Drug Trial Radar · NCT01849926
Ibuprofen Versus Mecillinam for Uncomplicated Cystitis
Last checked: Nov 20, 2026Latest source record: Nov 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
383
Actual
Start
Apr 2013
Primary completion
Jul 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- University of OsloAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Bergen; Lund University; University of Copenhagen
- First posted
- May 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Although uncomplicated cystitis is considered to be a mild condition and mostly self limiting, most patients who see a doctor will be treated with antibiotics. Antibiotics are known to give a quick relief of symptoms and shorten the course of the condition by a few days. The aim of this study is to evaluate ibuprofen versus mecillinam in the treatment of uncomplicated cystitis in otherwise healthy, non-pregnant women. Our main objective is to see whether symptomatic treatment with ibuprofen is equally efficient as treatment with mecillinam in this group.
Conditions
- Acute Cystitis (Excl in Pregnancy)
Interventions
IbuprofenDrug
MecillinamDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients who are symptom free by day fourTime frame: Four days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Oslo
Oslo, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.